Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors-Reference-Cited by-同舟云学术

Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors

Published:2021-07-14 Issue:9 Volume:28 Page:727-739
ISSN:1868-6974
Container-title:Journal of Hepato-Biliary-Pancreatic Sciences
language:en
Short-container-title:J Hepatobiliary Pancreat Sci

Author:

Kobayashi Noritoshi¹^ORCID,Wild Damian²,Kaul Felix²,Shimamura Takeshi³,Takano Shoko⁴,Takeda Yuma¹,Okubo Naoki¹,Suzuki Akihiro¹,Tokuhisa Motohiko¹,Ichikawa Yasushi¹

Affiliation:

1. Department of Oncology Yokohama City University Graduate School of Medicine Yokohama Japan

2. Division of Nuclear Medicine University Hospital Basel Basel Switzerland

3. Shimamura Clinic Kawasaki Japan

4. Department of Radiation Oncology Yokohama City University Graduate School of Medicine Yokohama Japan

Publisher

Wiley

Subject

Hepatology,Surgery

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jhbp.1014

Reference29 articles.

1. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors

2. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

3. Somatostatin Receptor 2–Targeting Compounds

4. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

5. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience;Neuroendocrinology;2024

2. Somatostatin receptor 2 in 10 different types of human non-neoplastic gastrointestinal neuroendocrine cells;Pathology - Research and Practice;2023-04

3. Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors;Cancers;2022-07-07

4. Neuroendocrine tumor theranostics;Cancer Science;2022-04-11

5. Lutetium-(177Lu)-oxodotreotide/Yttrium-90-DOTATOC;Reactions Weekly;2021-12